Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

COVID-19 vaccine vial maker Stevanato preps IPO valuing it at up to $5 billion: sources

Published 02/25/2021, 07:31 AM
Updated 02/25/2021, 07:35 AM
© Reuters. FILE PHOTO: A medical worker at the COVID-19 mass vaccination centre at the Cecchignola military compound, in Rome, Italy

By Abhinav Ramnarayan, Arno Schuetze and Elisa Anzolin

LONDON (Reuters) - Italy's Stevanato Group, manufacturer of glass vials for COVID-19 vaccines and other healthcare products, is making plans for an initial public offering this year that could value the company at between $4 billion-$5 billion, three sources with knowledge of the situation told Reuters.

Bank of America (NYSE:BAC) and Morgan Stanley (NYSE:MS) are among the banks appointed for the stock market listing which is expected to take place in New York, two of the sources added.

Spokespersons for Bank of America and Morgan Stanley declined to comment.

One of the sources said the healthcare packaging company would look to raise around $500 million from the IPO.

The company wants to capitalize on strong investor demand for healthcare assets but a final decision on whether to list in New York or possibly Milan has yet to be made, the sources said.

A spokesman for the company declined to comment.

The Padua-based firm, which is owned by Italy's Stevanato family, makes glass tube containers for the pharmaceutical and healthcare sectors and glass cartridges for insulin pen injectors.

It reported core earnings of 111.1 million euros ($135.88 million) in 2019 and a turnover of 570.3 million euros, the company said.

Its estimated valuation is based on how major peers such as U.S. drug packaging company West Pharma is trading, said one of the sources. West Pharma has a market capitalisation of $20.7 billion.

Last year, Stevanato signed an agreement with the global Coalition for Epidemic Preparedness Innovations - which is a co-leader of the World Health Organization's global vaccine-sharing scheme COVAX - for the supply of 100 million glass vials to hold up to 2 billion doses of a vaccine against the COVID-19 virus.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Stocks in the healthcare sector have soared since the start of the COVID-19 pandemic, particularly of those companies making products to combat the spread of the novel coronavirus.

New York's Nasdaq exchange is the world's biggest investment hub for biotechnology companies and its biotech index has a market cap of $1.3 trillion dollars.

($1 = 0.8177 euros)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.